Online inquiry

IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12201MR)

This product GTTS-WQ12201MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12201MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13510MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PRX002
GTTS-WQ14565MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aCD1919
GTTS-WQ2412MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 145
GTTS-WQ1321MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ5674MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDX-011
GTTS-WQ2774MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ5784MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ11611MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MGD-006
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW